Types of Tumor Vascularization

Slides:



Advertisements
Similar presentations
Avances en el tratamiento del Cáncer de Pulmón Lugar de la Angiogénesis en el tratamiento de segunda linea del CPCNP Carlos Camps Inducing angiogenesis.
Advertisements

AT 4 Receptor Ligands as Angiogenic, Anti-angiogenic, and Anti-cancer Agents How do you translate basic science into a clinically useful technology?
Tumors and Blood Vessels By: Dimitri, Amy, Idil, Bianca.
Figure 13.2 The Biology of Cancer (© Garland Science 2007) Hodgkins Lymphoma – A Cancer in Which 99% of the Tumor Cells Are Not Cancer Cells.
MBBS Cancer Biology Module 2006 Tumour Vasculature and Therapeutic Strategies Barbara Pedley.
ANTIANGIOGENESIS Anticancer Therapy By: Laura Roberts.
Mohamed El Mansy Matthew Flister Denan Wang Under supervision of Professor Daniel Sem.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Angiogenesis ↓ Metastasis. Angiogenesis--- The process of developing new blood vessels. Cancer cells (probably like all tissues) secrete substances that.
Inhibition of angiogenesis
Vasculogenesis and angiogenesis Integrins in vasculature and KO phenotypes Growth Factor Receptors signaling and vasculature phenotypes VEGFR Tip cells.
Adjuvant systemic therapy in breast cancer Targeted therapies Update R. Paridaens Belgian Breast Meeting
I.Cancer Cancer cells evolve and accumulate traits that distinguish them from normal cells causing them to form tumors cancer cellnormal cell Matthew Saelzler.
CANCER. Cancer: Caused by a mutation in a gene that codes for a checkpoint protein. The cell loses control over cell division and so divides at a rapid.
Modern aspects of drugs production. Differences.
Fibroblast Growth Factors (FGFs)
Microbubble-Ultrasound Radioenhancement of Bladder Cancer William Tyler Tran Radiation Therapist & Clinical Research Associate Department of Radiation.
TUMOR ANGIOGENESIS. Formation of new blood vessels is called angiogenesis Tumor angiogenesis is the proliferation of a network of blood vessels that penetrates.
1 Molecular Origins of Cancer Tumor Angiogenesis N Engl J Med 2008;358:
Cancer.
Angiotensin signalling in GBM: AT2R as a novel therapeutic target
The Cell Cycle and Cancer
Angiogenesis and hepatocellular carcinoma
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight  Giuseppe Aprile, Elena Ongaro, Marzia Del Re, Stefania.
Lecture 7: Selective Targeting of Cancer Cells
Inducing Angiogenesis
✔ ✔ ✔ CHECKPOINTS: STOP OR GO? MITOSIS & Cytokinesis
by Jennifer Couzin-Frankel
Inducing Angiogenesis
A surrogate marker to monitor angiogenesis at last
The PI3K/Akt signalling and its activation in cancer
Esther Bridges, Adrian L. Harris  Cancer Cell 
Multiple Effects of Angiopoietin-2 Blockade on Tumors
(A) An overview of the JAK/STAT signalling pathway.
Angiogenesis.
Molecular approaches to HER2 targeted therapy
Macrophages and Therapeutic Resistance in Cancer
Figure 2 from Sancho et al.
The cancer stem cell concept in cancer progression and metastasis
Macrophages and Therapeutic Resistance in Cancer
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Angiogenesis and hepatocellular carcinoma
VEGF signals via a paracrine loop to VEGFR-2 in the glomerulus.
The development and use of vascular targeted therapy in ovarian cancer
Vascular Endothelial Growth Factor (VEGF) Pathway
Understanding the Importance of Smart Drugs in Renal Cell Carcinoma
The Cell Cycle and Cancer
Vascular frontiers without borders
Sarah Otih Mentor: Dr. William Barton
TGF-β Receptor I/ ALK-5 and Pancreatic and Biliary Cancer
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer  Thomas Winder, Heinz–Josef.
Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth
Process and mechanisms of blood vessel formation.
Multiple Effects of Angiopoietin-2 Blockade on Tumors
Hit 'Em Where They Live: Targeting the Cancer Stem Cell Niche
Volume 22, Issue 2, Pages (August 2012)
The VEGF Family, the Inside Story
New drug toxicities in the onco-nephrology world
Angiogenesis and Angiostatin
Intratumoral hypoxia, radiation resistance, and HIF-1
The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc
Cancer Treatment.
Post-ischemic vascular repair mechanisms and the growth factors involved. Post-ischemic vascular repair mechanisms and the growth factors involved. The.
A, the knowledge acquired on canonical NOTCH signaling offers several targets to modulate the pathway. A, the knowledge acquired on canonical NOTCH signaling.
Ping-Pui Wong, Natalia Bodrug, Kairbaan M. Hodivala-Dilke 
by Jennifer Couzin-Frankel
- EVALUATION OF ISOLATION AND ANALYSIS SYSTEM FOR CTCS.
Normalizing the tumor microenvironment
Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.
Vascular frontiers without borders
Presentation transcript:

Types of Tumor Vascularization Angiogenesis Vasculogenic memory -Tumor cells may act like endothelial cells and form vascular-like structures

Types of Tumor Vascularization 3. Vasculogenesis -Differentiation and proliferation from endothelial progenitor cells -They are drawn to the tumor via VEGF -Upon reaching the tumor they differentiate -40% of tumor endothelial, especially lymphomas and colon cancers

Anti-Angiogenic Therapies -Cut off the tumor’s blood flow rather than target the tumor directly -Result: Cut off nutrients the tumor needs to grow

Anti-Angiogenic Therapies

Blocking VEGF Signaling Block Ligand, VEGF Block Receptor, VEGFR-2 Results: -Transient -Stop after treatment is stopped

Vascular Disrupting Agents -Destroy the existing vasculature in the tumor -Possible because of the differences between normal and tumor vasculature Combretastatin

Vascular Disrupting Agents Liposomes coated with NGR peptide (Asparagin, glycine, arginine) would be targeted to the tumor endothelial cell specific marker, aminopeptidase -Liposomes contain the drug Bortezomib (for neuroblastoma) Results: mice lived longer with less toxicity